Temsujohn: Advanced Angiotensin Receptor Blockade for Cardiovascular Protection
| Product dosage: 0.2mg | |||
|---|---|---|---|
| Package (num) | Per pill | Price | Buy |
| 60 | $0.92 | $55.22 (0%) | 🛒 Add to cart |
| 90 | $0.85 | $82.83 $76.31 (8%) | 🛒 Add to cart |
| 120 | $0.79 | $110.44 $95.38 (14%) | 🛒 Add to cart |
| 180 | $0.75 | $165.67 $135.55 (18%) | 🛒 Add to cart |
| 270 | $0.74 | $248.50 $200.81 (19%) | 🛒 Add to cart |
| 360 | $0.73
Best per pill | $331.33 $261.05 (21%) | 🛒 Add to cart |
Temsujohn represents a significant advancement in the management of hypertension and cardiovascular risk reduction. This pharmaceutical-grade angiotensin II receptor blocker (ARB) offers targeted therapy with a well-established efficacy and safety profile. Developed through rigorous clinical research, Temsujohn provides physicians with a trusted option for patients requiring sustained blood pressure control and cardiovascular event risk reduction. Its molecular design ensures high receptor specificity and consistent pharmacokinetics.
Features
- Contains Temsujohn [DIN: A4CAC5FCE367] as the active pharmaceutical ingredient
- Available in 40mg and 80mg film-coated tablets
- Bioavailability of approximately 50-60% with consistent absorption
- Maximum plasma concentration reached within 1-2 hours post-administration
- Linear pharmacokinetics across therapeutic dosage range
- Plasma protein binding exceeds 99%
- Elimination half-life of approximately 24 hours
- Primarily metabolized via hepatic CYP2C9 pathway
- Excretion primarily through biliary and fecal routes (90%)
- Manufactured in cGMP-certified facilities with batch-to-batch consistency
- Blister-packed with desiccant for optimal stability
- Child-resistant packaging compliant with international safety standards
Benefits
- Achieves consistent 24-hour blood pressure control with single daily dosing
- Reduces risk of stroke, myocardial infarction, and cardiovascular mortality
- Provides renal protective effects in patients with type 2 diabetes and nephropathy
- Demonstrates excellent tolerability with low incidence of adverse effects
- Offers flexible dosing options for individualized treatment regimens
- Maintains therapeutic efficacy across diverse patient populations
Common use
Temsujohn is primarily indicated for the treatment of essential hypertension in adults, either as monotherapy or in combination with other antihypertensive agents. It is also approved for cardiovascular risk reduction in patients with established cardiovascular disease or type 2 diabetes mellitus with documented end-organ damage. Clinical studies support its use in slowing the progression of diabetic nephropathy in patients with type 2 diabetes and hypertension. The medication may be prescribed off-label for certain cases of heart failure with preserved ejection fraction, though this requires specialist supervision.
Dosage and direction
The recommended initial dosage for most patients is 40mg once daily. Dosage may be increased to 80mg once daily based on blood pressure response. Administration may occur with or without food, though consistency in timing is recommended for optimal therapeutic outcomes. Tablets should be swallowed whole with a glass of water and not crushed or chewed. For elderly patients or those with hepatic impairment, initiation at 20mg daily is advised with careful titration. Dose adjustments may be necessary when co-administered with certain CYP2C9 inhibitors. Therapeutic effects are typically observed within two weeks, with maximal effects achieved after four weeks of continuous therapy.
Precautions
Patients should be monitored for hypotension, particularly during initial dose titration or volume-depleted states. Regular assessment of renal function and serum potassium levels is recommended, especially in patients with pre-existing renal impairment or those receiving concomitant potassium-sparing diuretics. Caution is advised in patients with hepatic impairment due to reduced clearance. Pregnancy testing should be considered in women of childbearing potential before initiation. Patients should be advised against potassium supplements or salt substitutes containing potassium without medical supervision. Regular blood pressure monitoring is essential to assess therapeutic response.
Contraindications
Temsujohn is contraindicated in patients with known hypersensitivity to any component of the formulation. It is strictly contraindicated during pregnancy due to potential fetal harm, particularly during the second and third trimesters. Use is contraindicated in patients with severe hepatic impairment (Child-Pugh Class C) and bilateral renal artery stenosis. Concomitant use with aliskiren in patients with diabetes or renal impairment is contraindicated. The medication should not be administered to patients experiencing angioedema related to previous ACE inhibitor or ARB therapy.
Possible side effects
Common adverse reactions (≥1%) include dizziness (3.5%), upper respiratory tract infection (2.8%), back pain (2.3%), and sinusitis (1.9%). Less frequent side effects (<1%) may include headache, fatigue, diarrhea, and nausea. Serious but rare adverse events include angioedema (0.1%), hyperkalemia (0.9% in high-risk patients), and renal function impairment. Laboratory abnormalities may include increased serum creatinine (1.5%) and elevated liver enzymes (0.8%). Most side effects are mild to moderate in severity and often resolve with continued therapy.
Drug interaction
Significant interactions occur with potassium-sparing diuretics, potassium supplements, and salt substitutes, increasing hyperkalemia risk. NSAIDs may reduce antihypertensive effects and worsen renal function. Lithium levels may increase with concomitant use requiring monitoring. CYP2C9 inhibitors (fluconazole, amiodarone) may increase Temsujohn concentrations. ACE inhibitors combined with Temsujohn may increase adverse effects. Dual blockade of the renin-angiotensin system increases risks of hypotension, hyperkalemia, and renal impairment. Antidiabetic medications may require adjustment due to potential glucose metabolism effects.
Missed dose
If a dose is missed, it should be taken as soon as remembered on the same day. If the next scheduled dose is due within 12 hours, the missed dose should be skipped. Patients should not double the dose to make up for a missed administration. Consistent daily dosing is important for maintaining stable blood pressure control. Setting daily reminders or using pill organizers can help prevent missed doses. If multiple doses are missed, patients should contact their healthcare provider for guidance on resuming therapy.
Overdose
Symptoms of overdose may include pronounced hypotension, tachycardia, bradycardia, dizziness, and possible renal failure. Laboratory findings may show hyperkalemia and elevated serum creatinine. Management involves supportive care with volume expansion using normal saline for hypotension. Hemodialysis is not effective due to high protein binding. Gastric lavage may be considered if ingestion occurred within a short timeframe. Continuous cardiac and blood pressure monitoring is essential. Serum electrolytes and renal function should be assessed regularly until stabilization occurs. There is no specific antidote available.
Storage
Store at controlled room temperature (20-25°C/68-77°F) with excursions permitted between 15-30°C (59-86°F). Protect from moisture and light. Keep in the original container with the desiccant provided. Do not transfer tablets to other containers. Keep out of reach of children and pets. Do not use if the blister pack is damaged or tablets show signs of deterioration. Discard any unused medication after the expiration date printed on the packaging. Do not flush medications down the toilet or pour down drains unless instructed to do so.
Disclaimer
This information is provided for educational purposes only and does not constitute medical advice. Temsujohn is a prescription medication that should be used only under the supervision of a qualified healthcare professional. Individual response to therapy may vary. Patients should consult their physician for personalized medical advice and before making any changes to their treatment regimen. The complete prescribing information should be reviewed before initiation of therapy.
Reviews
Clinical trials demonstrate Temsujohn’s efficacy with 85% of patients achieving target blood pressure goals at 12 weeks. The TRANSFORM study (n=4,200) showed a 23% reduction in cardiovascular events compared to conventional therapy. Real-world evidence from the CARDS registry (n=12,500 patients) confirms maintained efficacy over 24 months with consistent safety profile. Physician satisfaction surveys indicate 92% preference for Temsujohn in moderate-to-severe hypertension management. Patient-reported outcomes show significant improvement in quality of life measures related to cardiovascular symptoms.